The US subsidiary of Japanese pharmaceutical company Daiichi Sankyo said that, if approved, WelChol will be the first LDL cholesterol-lowering medication also indicated for improving glycemic control.
Clinical studies have shown that WelChol lowers A1C in patients with type 2 diabetes mellitus, according to the company, including one recently presented at the American Heart Association’s Scientific Sessions 2006 in Chicago.
Joseph Pieroni, president and CEO of Daiichi Sankyo Inc, said: “Given the prevalence of type 2 diabetes and high cholesterol and the number of patients who are not reaching goal, adding WelChol expands patients’ treatment options.”